dEV-000

dEV-000 is a preclinical-stage exosome-based therapeutic candidate developed by Shine Out Bio Technology for the treatment of Parkinson's disease and other neurodegenerative disorders. The drug utilizes a specialized exosome delivery platform engineered to cross the blood-brain barrier (BBB) and specifically target neurons. By leveraging the natural transport properties of exosomes, dEV-000 aims to deliver therapeutic payloads directly to affected brain regions, potentially improving efficacy and reducing systemic side effects compared to conventional treatments. Preclinical data indicates promising results in neurodegenerative models, particularly for Parkinson's disease.